Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% above its 5-year average of -335.94%, near the high end of its 5-year range (-14434.20%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -303.80%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
-303.80%
GROSS MARGIN AVG 3Y
-559.90%
GROSS MARGIN AVG 5Y
-335.94%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aprea Therapeutics, Inc.
Market Cap
$8.17M
Gross Margin
0.00%
TTM Avg
-303.80%
3Y Avg
-559.90%
5Y Avg
-335.94%
Market Cap
$8.33M
Gross Margin
-41.30%
TTM Avg
-15.77%
3Y Avg
-3.50%
5Y Avg
-3.50%
Market Cap
$7.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.91M
Gross Margin
N/A
TTM Avg
-2933.43%
3Y Avg
-1696.98%
5Y Avg
-1166.77%
Market Cap
$8.49M
Gross Margin
18.37%
TTM Avg
19.16%
3Y Avg
20.84%
5Y Avg
23.00%
Market Cap
$7.83M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.17M | 0.00% | -303.80% | -559.90% | -335.94% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.33M | -41.30% | -15.77% | -3.50% | -3.50% |
| GT Biopharma, Inc. (GTBP)vs › | $7.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| HeartSciences Inc. (HSCS)vs › | $7.91M | N/A | -2933.43% | -1696.98% | -1166.77% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.49M | 18.37% | 19.16% | 20.84% | 23.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.37M | 0.00% | 0.00% | 4.26% | 4.26% |
| Longeveron Inc. (LGVN)vs › | $7.33M | 69.76% | 72.87% | 54.39% | 49.20% |
| KALA BIO, Inc. (KALA)vs › | $7.35M | 0.00% | 0.00% | 8.55% | 24.65% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -1519.00% |
| 2025-03-31 | -1428.39% |
| 2024-12-31 | -1046.21% |
| 2024-09-30 | -702.66% |
| 2024-06-30 | -355.45% |
| 2024-03-31 | -320.52% |
| 2023-12-31 | -14434.20% |
| 2023-09-30 | -564.42% |
| 2023-06-30 | -782.16% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
